ATE321147T1 - Auf zellen gegründetes phosphodiesterase-10a- assay und sequenzen - Google Patents
Auf zellen gegründetes phosphodiesterase-10a- assay und sequenzenInfo
- Publication number
- ATE321147T1 ATE321147T1 AT02254973T AT02254973T ATE321147T1 AT E321147 T1 ATE321147 T1 AT E321147T1 AT 02254973 T AT02254973 T AT 02254973T AT 02254973 T AT02254973 T AT 02254973T AT E321147 T1 ATE321147 T1 AT E321147T1
- Authority
- AT
- Austria
- Prior art keywords
- agent
- cgmp
- camp
- submaximally
- administering
- Prior art date
Links
- 101001072037 Homo sapiens cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Proteins 0.000 title abstract 2
- 238000003556 assay Methods 0.000 title abstract 2
- 102100036377 cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Human genes 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 abstract 3
- 230000003213 activating effect Effects 0.000 abstract 2
- 210000002569 neuron Anatomy 0.000 abstract 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 abstract 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 abstract 1
- 108010078321 Guanylate Cyclase Proteins 0.000 abstract 1
- 102000014469 Guanylate cyclase Human genes 0.000 abstract 1
- 229940123773 Phosphodiesterase 10A inhibitor Drugs 0.000 abstract 1
- 101100028927 Rattus norvegicus Pde10a gene Proteins 0.000 abstract 1
- 102000030621 adenylate cyclase Human genes 0.000 abstract 1
- 108060000200 adenylate cyclase Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229960001789 papaverine Drugs 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30897801P | 2001-07-31 | 2001-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE321147T1 true ATE321147T1 (de) | 2006-04-15 |
Family
ID=23196146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02254973T ATE321147T1 (de) | 2001-07-31 | 2002-07-16 | Auf zellen gegründetes phosphodiesterase-10a- assay und sequenzen |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20030096323A1 (de) |
| EP (1) | EP1281771B1 (de) |
| JP (3) | JP2003135079A (de) |
| AT (1) | ATE321147T1 (de) |
| CA (1) | CA2391117A1 (de) |
| DE (1) | DE60210014T2 (de) |
| ES (1) | ES2256415T3 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030032579A1 (en) * | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| US8338420B1 (en) | 2002-12-04 | 2012-12-25 | Mitsubishi Tanabe Pharma Corporation | Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor |
| CA2520803A1 (en) * | 2003-04-03 | 2004-10-21 | Memory Pharmaceuticals Corporation | Phosphodiesterase 10a7 isoforms and methods of use |
| WO2005012485A2 (en) * | 2003-07-31 | 2005-02-10 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
| WO2010127186A1 (en) | 2009-04-30 | 2010-11-04 | Prognosys Biosciences, Inc. | Nucleic acid constructs and methods of use |
| US20190300945A1 (en) | 2010-04-05 | 2019-10-03 | Prognosys Biosciences, Inc. | Spatially Encoded Biological Assays |
| US10787701B2 (en) | 2010-04-05 | 2020-09-29 | Prognosys Biosciences, Inc. | Spatially encoded biological assays |
| DK2556171T3 (en) | 2010-04-05 | 2015-12-14 | Prognosys Biosciences Inc | Spatially CODED BIOLOGICAL ASSAYS |
| US20120258871A1 (en) | 2011-04-08 | 2012-10-11 | Prognosys Biosciences, Inc. | Peptide constructs and assay systems |
| GB201106254D0 (en) | 2011-04-13 | 2011-05-25 | Frisen Jonas | Method and product |
| WO2014060483A1 (en) | 2012-10-17 | 2014-04-24 | Spatial Transcriptomics Ab | Methods and product for optimising localised or spatial detection of gene expression in a tissue sample |
| WO2014145047A1 (en) | 2013-03-15 | 2014-09-18 | Prognosys Biosciences, Inc. | Methods for detecting peptide/mhc/tcr binding |
| US9868979B2 (en) | 2013-06-25 | 2018-01-16 | Prognosys Biosciences, Inc. | Spatially encoded biological assays using a microfluidic device |
| WO2015070037A2 (en) | 2013-11-08 | 2015-05-14 | Prognosys Biosciences, Inc. | Polynucleotide conjugates and methods for analyte detection |
| EP4282977B1 (de) | 2015-04-10 | 2024-06-05 | 10x Genomics Sweden AB | Räumlich getrennte multiplex-nukleinsäureanalyse von biologischen proben |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0967284A1 (de) * | 1998-05-28 | 1999-12-29 | Pfizer Limited | Phosphodiesterasen |
-
2002
- 2002-07-16 AT AT02254973T patent/ATE321147T1/de not_active IP Right Cessation
- 2002-07-16 DE DE60210014T patent/DE60210014T2/de not_active Expired - Fee Related
- 2002-07-16 ES ES02254973T patent/ES2256415T3/es not_active Expired - Lifetime
- 2002-07-16 EP EP02254973A patent/EP1281771B1/de not_active Expired - Lifetime
- 2002-07-24 US US10/202,107 patent/US20030096323A1/en not_active Abandoned
- 2002-07-26 JP JP2002217718A patent/JP2003135079A/ja active Pending
- 2002-07-29 CA CA002391117A patent/CA2391117A1/en not_active Abandoned
-
2004
- 2004-07-08 US US10/887,276 patent/US20050026236A1/en not_active Abandoned
-
2005
- 2005-07-27 JP JP2005217435A patent/JP2006006337A/ja not_active Ceased
- 2005-07-27 JP JP2005217438A patent/JP2005328850A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003135079A (ja) | 2003-05-13 |
| US20030096323A1 (en) | 2003-05-22 |
| ES2256415T3 (es) | 2006-07-16 |
| CA2391117A1 (en) | 2003-01-31 |
| EP1281771A3 (de) | 2004-01-02 |
| JP2006006337A (ja) | 2006-01-12 |
| DE60210014T2 (de) | 2006-09-21 |
| US20050026236A1 (en) | 2005-02-03 |
| JP2005328850A (ja) | 2005-12-02 |
| EP1281771A2 (de) | 2003-02-05 |
| EP1281771B1 (de) | 2006-03-22 |
| DE60210014D1 (de) | 2006-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60210014D1 (de) | Auf Zellen gegründetes Phosphodiesterase-10A-Assay und Sequenzen | |
| Chuang et al. | Sildenafil, a type-5 CGMP phosphodiesterase inhibitor, specifically amplifies endogenous cGMP-dependent relaxation in rabbit corpus cavernosum smooth muscle in vitro | |
| Murgia et al. | Oxidized ATP. An irreversible inhibitor of the macrophage purinergic P2Z receptor. | |
| DE50302975D1 (de) | Neue xanthinderivate, deren herstellung und deren verwendung als arzneimittel | |
| Vlahakis et al. | Synthesis and evaluation of azalanstat analogues as heme oxygenase inhibitors | |
| ATE481497T1 (de) | Am n-terminus trunkierte isoformen von zyklischen phosphodiesterasen pde3a | |
| DE502004006507D1 (de) | Imidazopyridazinon- und imidazopyridonderivate, deren herstellung und deren verwendung als arzneimittel | |
| EP1409544A4 (de) | Humane dr4-antikörper und deren anwendungen | |
| EA200602062A1 (ru) | Амидосоединения и их применение в качестве фармацевтических средств | |
| DE502005006204D1 (de) | 8- ä3-amino-piperidin-1-ylü-xanthine, deren herstellung und deren verwendung als arzneimittel | |
| ATE469911T1 (de) | Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung | |
| UY27807A1 (es) | Nuevos derivados de piridazin-3(2h)-ona | |
| HUP0105337A2 (hu) | Az immunválaszban szerepet játszó új polipeptidek | |
| ATE418555T1 (de) | A2a-adenosinrezeptorantagonisten | |
| ZA200508390B (en) | Compositions and methods for the therapy of inflammatory bowel disease | |
| ES2170222T3 (es) | Derivados c-nucleosidos y su utilizacion en la deteccion de acidos nucleicos. | |
| PA8461601A1 (es) | Isoquinolinas | |
| He et al. | Inhibitory effects of H1-antihistamines on CYP2D6-and CYP2C9-mediated drug metabolic reactions in human liver microsomes | |
| CA2525915A1 (en) | Pde10 cell-based assay and sequences | |
| DE50110723D1 (de) | Isolierte luziferasen sowie deren verwendung | |
| EP1879027A4 (de) | Mittel zur vorbeugung und behandlung einer pankreatitis | |
| DE60009530D1 (de) | Genetische toxizitätsmarker, herstellung und verwendung | |
| DE60106730D1 (de) | Aromatische aminhärter und ihre verwendung | |
| Fuertes et al. | Design, synthesis, and evaluation of octahydropyranopyrrole-based inhibitors of mammalian ribonucleotide reductase | |
| NO20065850L (no) | Fremgangsmate for identifisering av PDE5-modulatorer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |